Related Experiment Videos
Selective estrogen receptor modulators and postmenopausal health.
E B Roe1, K M Chiu, C D Arnaud
1University of California, Department of Medicine, San Francisco, USA.
Advances in Internal Medicine
|January 15, 2000
Summary
Selective estrogen receptor modulators (SERMs) offer benefits for postmenopausal women, including bone protection and potential cardiovascular advantages. Further research is needed to confirm long-term safety and efficacy for various conditions.
Area of Science:
- Endocrinology and Pharmacology
- Women's Health
- Oncology
Background:
- Selective Estrogen Receptor Modulators (SERMs) are a class of drugs with mixed estrogen agonist/antagonist properties.
- These agents show promise for managing postmenopausal changes, particularly osteoporosis and cardiovascular health.
- Concerns regarding hormone replacement therapy (HRT) side effects drive interest in SERMs.
Purpose of the Study:
- To review the efficacy and safety of SERMs, focusing on Raloxifene and Tamoxifen.
- To evaluate the potential of SERMs in preventing postmenopausal bone loss, fractures, and cardiovascular events.
- To explore the role of SERMs in primary breast cancer prevention.
Main Methods:
- Review of existing literature on SERM clinical trials and pharmacological profiles.
- Analysis of data regarding effects on bone mineral density, lipoprotein levels, and uterine tissue.
- Evaluation of evidence for breast cancer risk reduction and prevention.
Main Results:
- Raloxifene effectively prevents bone loss and may reduce fractures in postmenopausal osteoporosis, with cardioprotective lipoprotein changes and no uterine stimulation.
- Tamoxifen is effective for primary breast cancer prevention in high-risk women, offering bone and lipoprotein benefits.
- Newer SERMs are in development with potentially enhanced tissue-specific effects.
Conclusions:
- Raloxifene is a viable alternative to HRT for postmenopausal bone loss, especially for women concerned about breast cancer or bleeding risks.
- Further long-term studies are required to ascertain Raloxifene's impact on fractures, cardiac events, dementia, and primary breast cancer prevention.
- The future likely involves a selection of tailored SERMs based on individual patient profiles and risk factors.